Back to Atlas
BSemi-durableStandard research/education caution
CMP-0179
Approved in some countries
Cerebrolysin
Nootropic / Neuroregenerative
Neurorecovery, stroke/TBI/dementia support positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Peptide mixture
- Primary mechanism
- Neurotrophic peptide mixture
- Primary market use
- Neurorecovery
Pharmacology
- Molecular weight (Da)
- Mixture / variable
- Oral bioavailability
- N/A
- Half-life
- Variable; short peptides
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- Human
- Clinical status
- Approved in some countries
- Value-for-money score
- 5 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Effects may include rehabilitation-linked durable gains